BioCentury
ARTICLE | Clinical News

VZIG antibody to the chickenpox virus: CNJ will start a Phase II trial

September 9, 1996 7:00 AM UTC

Cangene Corp. (TSE:CNJ), Mississauga, Ontario Product: VZIG antibody to the chickenpox virus (Varicella zoster) Indication: Post-herpetic neuralgia after shingles Status: CNJ will start a Phase II tr...